IMR Press / RCM / Volume 12 / Issue 3 / DOI: 10.3909/ricm0572

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
The Electrophysiological Properties of Ranolazine: A Metabolic Anti-Ischemic Drug or an Energy-Efficient Antiarrhythmic Agent?
Show Less
1 Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA
2 Division of Cardiology, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA
Rev. Cardiovasc. Med. 2011, 12(3), 136–142;
Published: 30 September 2011
Ranolazine, a newer anti-ischemic agent that appears to induce a more efficient utilization of adenosine triphosphate at the cellular level, has been shown to be clinically beneficial in patients with chronic stable angina. More recently, the antiarrhythmic effects of the drug have been described in patients with acute coronary syndromes, as well as in those with atrial fibrillation, when combined with other agents. Experimentally, the predominant inhibitory effects on late INa, ICa, INa-Ca, and IKs, with little or no effect on Ito or IK1, have been demonstrated. Different experimental models have shown the potential beneficial effect of the drug in both supraventricular and ventricular arrhythmias. Interestingly, despite its potential prolongation of the QT interval, ranolazine does not appear to induce ventricular arrhythmias in animal models. Whether the antiarrhythmic effect is secondary to a more efficient energy production by the cardiac cell or by its direct effect on ion channels is still unclear. The effect of ranolazine on other ionic currents, as well as its potential as a clinically relevant antiarrhythmic agent, still needs to be studied.
Anti-ischemic agents
Mechanisms of arrhythmias
Back to top